Abstract:

Objective To investigate the influence of IL-17A-OVA vaccine to experimental autoimmune uveoretinitis (EAU). Design Experimental study. Participants Thirty C57BL6 mouses. Methods To produce  IL-17A-OVA vaccine. Thirty C57BL6 mouses were equally divided into adjuvant group, vaccine group and Cyclosporine (CsA) group at random. The first two groups were immunized by IL-17A-OVA or adjuvant firstly. Then EAU with interphotoreceptor retinoid-binding protein (IRBP) in the tenth week was induced. The latter group induced EAU firstly and then given CsA by intragastric administration for 2 weeks. Eyeball biopsy of mouse was observed with HE staining two weeks after EAU induction. IL-17A, IL-17A IgG, IL-6, IL-23 in the serum was measured with ELISA. Main Outcome Measures IL-17A, IL-17A IgG, IL-6 and IL-23 levels in mouse serum. Results HE staining shows that there were significant difference in histopathological score not only between adjuvant group and vaccine group, but also between adjuvant group and CsA group, there was no significant difference between vaccine group and CsA group. IL-17A of vaccine group and Cyclosporine group were significantly lower than adjuvant group (adjuvant group, 33.774±6.478 pg/ml; vaccine group , 25.785±4.677 pg/ml; CsA group, 23.129±3.940 pg/ml ; F=8.125, P=0.003). IL-17A IgG of vaccine group was higher than adjuvant group and CsA group, there was no significant difference between CsA group and adjuvant group(adjuvant group, 56.712±4.214 pg/ml; vaccine group, 106.379±12.603 pg/ml; CsA group, 59.431±8.626 pg/ml ; F=63.008, P=0.000). IL-6 of vaccine group and CsA group were significantly lower than adjuvant group (adjuvant group, 49.329±8.768 pg/ml ; vaccine group, 41.124±4.959 pg/ml; CsA group, 29.418±3.347 pg/ml; F=18.603, P=0.000). IL-23 of CsA group was significantly lower than vaccine group and adjuvant group, there was no significant difference between vaccine group and adjuvant group (adjuvant group, 109.770±20.848 pg/ml; vaccine group, 100.893±13.467 pg/ml; CsA group, 73.492±12.324 pg/ml; F=4.916, P=0.018). Conclusions IL-17A-OVA vaccine has infulunce in reducing the expression of EAU inflammation by the means of IL-17A IgG passway, and may be a new treatment to autoimmune uveitis. (Ophthalmol CHN, 2017, 26: 34-38)

Key words: IL-17A-OVA vaccine, cyclosporine, experimental autoimmune uveoretinitis